We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Molecular Tests Screens for Retinal Diseases

By LabMedica International staff writers
Posted on 01 Feb 2011
A custom resequencing chip has been designed to identify known and new mutations in retinal disease genes. More...


The retinal resequencing chip covers all exons of 90 retinal disease genes and it has been tested with multiplex primer sets for 1,445 amplicons representing the genes included on the chip.

A collaborative study carried out at the Netherlands Institute for Neuroscience (Amsterdam, The Netherlands), tested their retinal DNA resequencing chip and patient pooling strategy. This enabled detection of multiple retinal disease gene sequences in numerous patients, at the same time. DNA was extracted from peripheral blood from 60 patients with a variety of retinal disorders, including Leber's congenital amaurosis, ocular albinism, pseudoxanthoma elasticum, retinitis pigmentosa, and Stargardt's disease.

The custom 300-kb resequencing chip is designed for polymerase chain reaction (PCR) amplification, DNA fragmentation, and chip hybridization performance. Hybridization signals were analyzed using appropriate detection software and this resequencing approach was validated by Sanger sequence technology. The new chip can screen up to 90 retinal disease genes in as many as 20 patients at the same time and return results faster than current tests. Since 150 genes related to 30 retinal diseases have been identified, and on average, at least five genes must be considered for each type of disease.

Arthur A.B. Bergen, PhD, the lead author of the study, said, "In initial and replicated tests, we achieved a high 99% detection rates, 100% reproducibility of results and no false-positives. Unlike current methods, our chip can detect both known and new genetic sequence changes associated with retinal disorders, an advance that will further our understanding of disease mechanisms as well as improving diagnosis and treatment. The chip is fully validated for DNA diagnostic purposes, and an upgraded version will be available in early 2011 at the Netherlands Institute for Neuroscience, Amsterdam. The study was published in January 2011, in the journal Ophthalmology.

Related Links:
Netherlands Institute for Neuroscience



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.